Drug discovery and development company Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) announced today the company has identified three additional families of highly novel, non-tryptamine, next-generation psychedelic compounds through its discovery work.
The company which focuses on creating novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, Mindset announced in a press release that through the usage of fragment-based drug discovery (FBDD) method combined with a highly focused medicinal chemistry strategy, Mindset’s scientists designed and developed three new, chemically distinct, small molecule non-tryptamine scaffolds, Families 6, 7, and 8.
The company has filed provisional patent applications on these families, with favorable FTO searches. Approximately forty novel drug-like lead compounds were synthesized and evaluated in in-vitro hydroxy tryptamine (5-HT) subtype receptors and in in-vitro absorption, distribution, metabolism, and excretion (ADME) studies. To date, pre-clinical screening has shown significantly enhanced receptor functional potency and selectivity.
About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company striving to create optimized, patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Leveraging the therapeutic potential of psychedelic drugs, Mindset was established to bridge this gap in available treatments.
Mindset is developing several new families of psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 and 4.
Mindset Pharma Future Potential
Mindset believes some of the newly discovered compounds have the potential for greater central nervous system (CNS) penetration, oral activity, and efficacy.
In a recent exclusive interview with Psychedelic Chronicle, CEO James Lanthier discusses the previous 4 families at Mindset Pharma. You can read more here: Mindset Pharma CEO James Lanthier Exclusive Interview with Psychedelic Chronicle
Mr. Lanthier also shared a comment today on the breaking news regarding Families 6, 7, and 8 stating,
Mindset’s leading drug discovery engine continues to yield innovations with the potential to help patients across the world with neuropsychiatric and neurological disorders. The discovery of new Families 6, 7, and 8 demonstrates our commitment to expanding our Research & Development and strengthening our Intellectual Property (IP) portfolio beyond the classical tryptamines in the psychedelic field.
He further expanded on the discovery highlighting how the discovery will expand the company’s existing pipeline.
The discovery of these new families further expands our rich pipeline and provides a unique serotonergic receptor profile supporting our goal to design new and elegant drug candidates with increased receptor selectivity and potency profiles. Pre-clinical screening of the new families has shown promising results thus far and we are eagerly looking forward to advancing Mindset’s continued innovations into these new, chemically distinct drug families.
Since it was created, Mindset’s ambition has been to be the leading company in medical psychedelic space discovery by expanding the boundaries of known psychedelic drugs to create the most comprehensive portfolio of varied and innovative drug candidates. Most companies in this industry focus on classic psychedelics like tryptamine drugs (psilocybin and DMT), but Mindset hs pushed beyond that into new areas to develop what they believe to be better neuropsychiatric medications.
